Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors. HCLv is characterized by unfavorable prognosis, low complete remission rates and limited disease control following classical hairy cell leukemia-based regimens. In this study, we report 3 cases of elderly patients with treatment-naive, TP53 un-mutated HCLv, who were effectively treated with four cycles of bendamustine plus rituximab. The regimen was completed in all the patients with acceptable toxicity. All patients achieved a complete clinical response with no evidence of residual disease at bone marrow biopsy and flow-cytometry examination. After a median follow-up of 19 months, the 3 subjects are still in complete remission. In this work, bendamustine plus rituximab proved to be an effective and feasible first-line treatment strategy for elderly patients with TP53 un-mutated HCLv.
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases
Visentin, AndreaMembro del Collaboration Group
;Imbergamo, SilviaMembro del Collaboration Group
;Frezzato, FedericaMembro del Collaboration Group
;Pizzi, MarcoMembro del Collaboration Group
;Bertorelle, RobertaMembro del Collaboration Group
;Scomazzon, EdoardoMembro del Collaboration Group
;Berno, TamaraMembro del Collaboration Group
;Riva, MarcelloMembro del Collaboration Group
;Piva, ElisaMembro del Collaboration Group
;Facco, MonicaMembro del Collaboration Group
;Piazza, FrancescoMembro del Collaboration Group
;Semenzato, Gianpietro;Trentin, Livio
Membro del Collaboration Group
2017
Abstract
Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors. HCLv is characterized by unfavorable prognosis, low complete remission rates and limited disease control following classical hairy cell leukemia-based regimens. In this study, we report 3 cases of elderly patients with treatment-naive, TP53 un-mutated HCLv, who were effectively treated with four cycles of bendamustine plus rituximab. The regimen was completed in all the patients with acceptable toxicity. All patients achieved a complete clinical response with no evidence of residual disease at bone marrow biopsy and flow-cytometry examination. After a median follow-up of 19 months, the 3 subjects are still in complete remission. In this work, bendamustine plus rituximab proved to be an effective and feasible first-line treatment strategy for elderly patients with TP53 un-mutated HCLv.File | Dimensione | Formato | |
---|---|---|---|
21304-304084-3-PB.pdf
accesso aperto
Tipologia:
Published (publisher's version)
Licenza:
Accesso libero
Dimensione
1.29 MB
Formato
Adobe PDF
|
1.29 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.